1. Home
  2. FIVN vs KARD Comparison

FIVN vs KARD Comparison

Compare FIVN & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Five9 Inc.

FIVN

Five9 Inc.

HOLD

Current Price

$27.45

Market Cap

1.9B

Sector

Technology

ML Signal

HOLD

Logo Kardigan Inc. Common Stock

KARD

Kardigan Inc. Common Stock

N/A

Current Price

$20.81

Market Cap

1.8B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
FIVN
KARD
Founded
2001
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
1.9B
1.8B
IPO Year
2014
N/A

Fundamental Metrics

Financial Performance
Metric
FIVN
KARD
Price
$27.45
$20.81
Analyst Decision
Buy
Analyst Count
18
0
Target Price
$26.06
N/A
AVG Volume (30 Days)
2.4M
270.1K
Earning Date
04-30-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
364.71
N/A
EPS
0.21
N/A
Revenue
$1,149,088,000.00
N/A
Revenue This Year
$11.39
N/A
Revenue Next Year
$10.00
N/A
P/E Ratio
$132.40
N/A
Revenue Growth
10.28
N/A
52 Week Low
$13.29
$19.58
52 Week High
$28.86
$27.00

Technical Indicators

Market Signals
Indicator
FIVN
KARD
Relative Strength Index (RSI) 63.52 46.08
Support Level $17.66 $20.91
Resistance Level N/A $22.13
Average True Range (ATR) 1.67 1.73
MACD 0.23 -0.17
Stochastic Oscillator 81.91 28.78

Price Performance

Historical Comparison
FIVN
KARD

About FIVN Five9 Inc.

Five9 offers cloud-native contact center software enabling digital customer service, sales, and marketing engagement. The company's Intelligent CX platform combines core telephony functionality, omnichannel engagement, and modules into a cloud contact-center-as-a-service, or CCaaS, platform. Five9's modules include digital self-service, agent assist technology, workflow automation, and optimization solutions, as well as artificial intelligence-driven automation solutions that optimize customer service efficiency and manage interaction quality and agent performance.

About KARD Kardigan Inc. Common Stock

Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.

Share on Social Networks: